First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition

Academic Article

Abstract

  • © 2018 JNCCN - Journal of the National Comprehensive Cancer Network. Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to identify potential therapeutic targets in difficult-to-treat cancers such as SDC. This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a BRAF p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib. During his response interval, new data emerged to justify subsequent treatment with both an immune checkpoint inhibitor and androgen blockade after his disease progressed. To our knowledge, this is the first report of frontline BRAF-directed therapy eliciting a response in metastatic SDC.
  • Digital Object Identifier (doi)

    Pubmed Id

  • 21329885
  • Author List

  • Lin VTG; Nabell LM; Spencer SA; Carroll WR; Harada S; Yang ES
  • Start Page

  • 1166
  • End Page

  • 1170
  • Volume

  • 16
  • Issue

  • 10